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Introduction
Hyper Immunoglobulin D syndrome (HIDS) is a genetic
disorder characterized by recurrent attacks of fever and
inflammatory symptoms and is most common in those
of French or Dutch descent.[1,2]
Objectives
To understand the impact of HIDS on the lives of
patients/caregivers, to describe patient’s journey from first
symptoms and to learn what patients hope to emerge in
terms of future therapy, support and information.
Patients and methods
Fifteen patients with HIDS were recruited across US, Eur-
ope and Australia. They completed a 20 page pre-interview
questionnaire and an in-depth 90 minute in-home inter-
view. Patient responses were recorded and summarized; for
patients with complete data available (n=13), responses
were quantified. The topics covered in the interview were
symptoms, patient journey, and unmet needs.
Results
Patients reported periods of wellness and symptomatic
flares, where flares were characterised by high fevers
and nausea (especially in children), as well as pain. In
many cases flares were so severe that patients were bed-
ridden. In children, flares led to severely disrupted edu-
cation. In caregivers and adult patients, attacks and
medical appointments resulted in missed work and lim-
ited career choices, leading to financial dependency.
HIDS also had an impact on patients’ relationships
and social lives by limiting their activities. Severity of
symptoms, the duration and frequency of flares
decreased with age and treatment. Patients frequently
experienced a delay in diagnosis (15 mos-20 yrs), where
they were subjected to a variety of diagnostic tests for
other conditions. While most patients were initially trea-
ted with non-steroidal anti-inflammatories, colchicine,
or steroids; they transitioned to biological treatment.
Responses to biologic agents varied, although many
reported shorter attack duration and frequency, all
respondents continued to experience attacks. Around
half of patients have switched biologics due to lack of
efficacy. Patients and parents seek out information inde-
pendently at diagnosis, usually via the internet. Patients
identified improved treatment efficacy and reduced side
effects as the areas in greatest unmet need.
Conclusions
HIDS significantly impacts the physical, social, emotional
and practical/financial aspects of patients’ and caregivers’
lives. Greater awareness of HIDS among HCPs may
improve diagnostic delays. Patients expressed interests in
gaining a greater understanding of their disease and
treatment options. There is an unmet need for therapy
that prevents or reduces the number of attacks and
which has patient-friendly administration.
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